Cargando…
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
There is considerable potential for integrating transarterial chemoembolization (TACE), programmed death-(ligand)1 (PD-[L]1) inhibitors, and molecular targeted treatments (MTT) in hepatocellular carcinoma (HCC). It is necessary to investigate the therapeutic efficacy and safety of TACE combined with...
Ejemplares similares
-
Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
por: Jin, Zhi-Cheng, et al.
Publicado: (2023) -
Step-by-step strategy in the management of residual hepatolithiasis using post-operative cholangioscopy
por: Wen, Xu-dong, et al.
Publicado: (2017) -
Molecular detection and genetic diversity of Rickettsia spp. in pet dogs and their infesting ticks in Harbin, northeastern China
por: Shao, Jian-Wei, et al.
Publicado: (2021) -
Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients
por: Peng, Wen Hui, et al.
Publicado: (2011) -
Sudden Deaths Among Chinese Physicians
por: Song, Xin-Nan, et al.
Publicado: (2015)